Redhill Biopharma Stock Analysis
| RDHL Stock | USD 0.43 0.01 2.27% |
Redhill Biopharma is undervalued with Real Value of 10.32 and Target Price of 40.0. The main objective of Redhill Biopharma stock analysis is to determine its intrinsic value, which is an estimate of what Redhill Biopharma is worth, separate from its market price. There are two main types of Redhill Biopharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Redhill Biopharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Redhill Biopharma's stock to identify patterns and trends that may indicate its future price movements.
The Redhill Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Redhill Biopharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Redhill Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Redhill Biopharma's ongoing operational relationships across important fundamental and technical indicators.
Redhill |
Redhill Stock Analysis Notes
The company had not issued any dividends in recent years. Redhill Biopharma had 1:40 split on the 23rd of March 2023. RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Redhill Biophrma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 201 people. To find out more about Redhill Biopharma contact Ori Shilo at 972 3 541 3131 or learn more at https://www.redhillbio.com.Redhill Biopharma Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Redhill Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Redhill Biopharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Redhill Biopharma generated a negative expected return over the last 90 days | |
| Redhill Biopharma has high historical volatility and very poor performance | |
| Redhill Biopharma has some characteristics of a very speculative penny stock | |
| Redhill Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 1.17 M in liabilities with Debt to Equity (D/E) ratio of 9.89, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Redhill Biopharma has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Redhill Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Redhill Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Redhill Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Redhill to invest in growth at high rates of return. When we think about Redhill Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Redhill Biopharma currently holds about 28.86 M in cash with (35.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Redhill Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: AscellaHealth Expands Executive Team Industry Veterans Lead Development and Implementation of End-to-End Payer Solutions and Pharmacy Operations to Control Specialty Spend |
Redhill Biopharma Upcoming and Recent Events
Earnings reports are used by Redhill Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Redhill Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Redhill Largest EPS Surprises
Earnings surprises can significantly impact Redhill Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-11-19 | 2019-09-30 | -0.4 | -0.35 | 0.05 | 12 | ||
2018-08-30 | 2018-06-30 | -0.44 | -0.5 | -0.06 | 13 | ||
2022-06-23 | 2022-03-31 | -0.23 | -0.3 | -0.07 | 30 |
Redhill Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Redhill Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Redhill Biopharma backward and forwards among themselves. Redhill Biopharma's institutional investor refers to the entity that pools money to purchase Redhill Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2023-12-31 | 104 | Ubs Group Ag | 2023-12-31 | 104 | Bank Of America Corp | 2023-12-31 | 82.0 | Atlantic Edge Private Wealth Management Llc | 2023-12-31 | 25.0 | Wells Fargo & Co | 2023-12-31 | 23.0 | Jpmorgan Chase & Co | 2023-12-31 | 8.0 | Ifp Advisors, Llc | 2023-12-31 | 7.0 | Cowen And Company, Llc | 2023-09-30 | 0.0 | Virtu Financial Llc | 2023-12-31 | 0.0 | Gagnon Securities Llc | 2023-12-31 | 89.6 K | Jane Street Group, Llc | 2023-12-31 | 86.8 K |
Redhill Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.1 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Redhill Biopharma's market, we take the total number of its shares issued and multiply it by Redhill Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Redhill Profitablity
Redhill Biopharma's profitability indicators refer to fundamental financial ratios that showcase Redhill Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, Redhill Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Redhill Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Redhill Biopharma's profitability requires more research than a typical breakdown of Redhill Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 3.66 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is normal as compared to the sector avarege. Similarly, it shows Operating Margin (OM) of (10.61) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $10.61. | Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 1.37 | 1.44 | |
| Return On Capital Employed | (8.24) | (7.83) | |
| Return On Assets | 1.04 | 1.09 | |
| Return On Equity | 11.56 | 12.14 |
Management Efficiency
Redhill Biopharma has return on total asset (ROA) of (0.1571) % which means that it has lost $0.1571 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.8429) %, meaning that it created substantial loss on money invested by shareholders. Redhill Biopharma's management efficiency ratios could be used to measure how well Redhill Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Redhill Biopharma's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 1.09 this year, although the value of Return On Capital Employed is projected to rise to (7.83). At this time, Redhill Biopharma's Other Assets are quite stable compared to the past year. Return On Tangible Assets is expected to rise to 1.44 this year, although the value of Other Current Assets will most likely fall to about 757.2 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.32 | 0.30 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (0.54) | (0.51) | |
| Enterprise Value Over EBITDA | (0.15) | (0.15) | |
| Price Book Value Ratio | 4.57 | 4.17 | |
| Enterprise Value Multiple | (0.15) | (0.15) | |
| Price Fair Value | 4.57 | 4.17 | |
| Enterprise Value | 4.3 M | 4.1 M |
The analysis of Redhill Biopharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Redhill Biopharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Redhill Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 3.461 |
Technical Drivers
As of the 23rd of April, Redhill Biopharma holds the Variance of 52.14, risk adjusted performance of (0.07), and Coefficient Of Variation of (778.63). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Redhill Biopharma, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We have analyze and collected data for thirteen technical drivers for Redhill Biopharma, which can be compared to its competitors. Please check Redhill Biopharma coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and skewness to decide if Redhill Biopharma is priced some-what accurately, providing market reflects its current price of 0.43 per share. As Redhill Biopharma is a penny stock we also suggest to check out its jensen alpha numbers.Redhill Biopharma Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Redhill Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Redhill Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Redhill Biopharma Predictive Daily Indicators
Redhill Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Redhill Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 52567.67 | |||
| Daily Balance Of Power | (0.20) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 0.43 | |||
| Day Typical Price | 0.43 | |||
| Period Momentum Indicator | (0.01) |
Redhill Biopharma Forecast Models
Redhill Biopharma's time-series forecasting models are one of many Redhill Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Redhill Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Redhill Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Redhill Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Redhill shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Redhill Biopharma. By using and applying Redhill Stock analysis, traders can create a robust methodology for identifying Redhill entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 3.66 | 3.85 | |
| Operating Profit Margin | (4.81) | (5.05) | |
| Net Profit Margin | 3.67 | 3.86 | |
| Gross Profit Margin | 0.47 | 0.49 |
Current Redhill Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Redhill analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Redhill analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 40.0 | Strong Buy | 1 | Odds |
Most Redhill analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Redhill stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Redhill Biopharma, talking to its executives and customers, or listening to Redhill conference calls.
Redhill Stock Analysis Indicators
Redhill Biopharma stock analysis indicators help investors evaluate how Redhill Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Redhill Biopharma shares will generate the highest return on investment. By understating and applying Redhill Biopharma stock analysis, traders can identify Redhill Biopharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 36 M | |
| Common Stock Shares Outstanding | 6.5 M | |
| Total Stockholder Equity | 2.1 M | |
| Property Plant And Equipment Net | 1.2 M | |
| Cash And Short Term Investments | 6.4 M | |
| Cash | 6.4 M | |
| Accounts Payable | 3.3 M | |
| Net Debt | -5.2 M | |
| 50 Day M A | 0.5182 | |
| Total Current Liabilities | 19.2 M | |
| Other Operating Expenses | 37.9 M | |
| Non Current Assets Total | 6.9 M | |
| Forward Price Earnings | 1428.5714 | |
| Non Currrent Assets Other | 147 K | |
| Stock Based Compensation | 1.6 M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Redhill Stock analysis
When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 4 | Revenue Per Share 1.008 | Quarterly Revenue Growth (0.96) | Return On Assets (0.16) | Return On Equity (8.84) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.